ImmunityBio Beheer

Beheer criteriumcontroles 2/4

De CEO ImmunityBio is Rich Adcock, benoemd in Oct2020, heeft een ambtstermijn van 5.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.72M, bestaande uit 6.5% salaris en 93.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.054% van de aandelen van het bedrijf, ter waarde € 3.52M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.9 jaar en 5.8 jaar.

Belangrijke informatie

Rich Adcock

Algemeen directeur

US$12.7m

Totale compensatie

Percentage CEO-salaris	6.54%
Dienstverband CEO	5.7yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	4.9yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Rich Adcock's beloning veranderd ten opzichte van ImmunityBio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2026	n/a	n/a	-US$855m
Dec 31 2025	US$13m	US$832k	-US$351m
Sep 30 2025	n/a	n/a	-US$349m
Jun 30 2025	n/a	n/a	-US$367m
Mar 31 2025	n/a	n/a	-US$409m
Dec 31 2024	US$11m	US$802k	-US$414m
Sep 30 2024	n/a	n/a	-US$588m
Jun 30 2024	n/a	n/a	-US$598m
Mar 31 2024	n/a	n/a	-US$601m
Dec 31 2023	US$1m	US$796k	-US$583m
Sep 30 2023	n/a	n/a	-US$458m
Jun 30 2023	n/a	n/a	-US$473m
Mar 31 2023	n/a	n/a	-US$430m
Dec 31 2022	US$4m	US$791k	-US$417m
Sep 30 2022	n/a	n/a	-US$400m
Jun 30 2022	n/a	n/a	-US$376m
Mar 31 2022	n/a	n/a	-US$370m
Dec 31 2021	US$29m	US$765k	-US$347m
Sep 30 2021	n/a	n/a	-US$323m
Jun 30 2021	n/a	n/a	-US$301m
Mar 31 2021	n/a	n/a	-US$264m
Dec 31 2020	US$843k	US$141k	-US$222m

Compensatie versus markt: De totale vergoeding ($USD 12.72M ) Rich } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 2.60M ).

Compensatie versus inkomsten: De vergoeding van Rich is gestegen terwijl het bedrijf verliesgevend is.

CEO

Rich Adcock (57 yo)

5.7yrs

Tenure

US$12,716,953

Compensatie

Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Patrick Soon-Shiong	Founder	11.6yrs	US$12.29m	27.83% € 1.8b
Richard Adcock	President	5.7yrs	US$12.72m	0.053% € 3.5m
David Sachs	Chief Financial Officer	6.9yrs	US$4.24m	0.029% € 1.9m
Regan Lauer	Chief Accounting Officer	4.6yrs	US$745.31k	0.011% € 727.5k
Barry Simon	Chief Corporate Affairs Officer & Director	5.3yrs	geen gegevens	0.27% € 17.8m
Enrique Diloné	Chief Technology Officer	3.4yrs	geen gegevens	geen gegevens
Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	6.3yrs	geen gegevens	geen gegevens
Emily Arison	Senior Vice President of Human Resources	4.9yrs	geen gegevens	geen gegevens
Leonard Sender	Chief Medical Officer of Liquid Tumors & Cell Therapy	1.3yrs	geen gegevens	geen gegevens
Sandeep Reddy	Chief Medical Officer	5.8yrs	geen gegevens	geen gegevens
Hans Klingemann	Chief Science Officer of Cellular	no data	geen gegevens	geen gegevens
Manju Saxena	Senior VP of Product Development & Cell Therapy Program	2.4yrs	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 26CA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Patrick Soon-Shiong	Founder	11.6yrs	US$12.29m	27.83% € 1.8b
Richard Adcock	President	5.3yrs	US$12.72m	0.053% € 3.5m
Barry Simon	Chief Corporate Affairs Officer & Director	19.4yrs	geen gegevens	0.27% € 17.8m
Christobel Selecky	Independent Director	5.8yrs	US$477.28k	0% € 0
Wesley Clark	Independent Director	5.3yrs	US$470.59k	0.00076% € 50.0k
Bruce Wendel	Independent Director	less than a year	US$302.74k	geen gegevens
Michael Blaszyk	Independent Director	10.9yrs	US$513.38k	0.025% € 1.7m
Cheryl Cohen	Lead Independent Director	7yrs	US$514.19k	0.019% € 1.3m
Linda Maxwell	Independent Director	5.3yrs	US$489.19k	0% € 0

5.8yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 26CA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/06/10 23:50
Aandelenkoers aan het einde van de dag	2026/06/10 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

ImmunityBio, Inc. wordt gevolgd door 8 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Justin Zelin	BTIG
Suranjit Mukherjee	BTIG
Jason Kolbert	D. Boral Capital LLC.

ImmunityBio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

ImmunityBio, Inc., Annual General Meeting, Jun 09, 2026

ImmunityBio, Inc. Appoints Bruce Wendel to the Board, Effective December 12, 2025

ImmunityBio, Inc., Annual General Meeting, Jun 18, 2025

John Owen Brennan Resigns as a Member of the Board of Directors and from All Committees of the Board of ImmunityBio, Inc

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

Recent updates

ImmunityBio Announces FDA Acceptance Of Supplemental BLA For ANKTIVA Plus BCG In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Papillary Disease

Insufficient new directors

ImmunityBio, Inc., Annual General Meeting, Jun 09, 2026

ImmunityBio Announces Anktiva Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients

ImmunityBio Inc Addresses FDA Correspondence and Implements Enhanced Advertising Compliance Measures

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA Plus BCG Versus BCG Alone

ImmunityBio, Inc. Announces Approval For ANKTIVA In Macau Sar China For Bcg-Unresponsive Nmibc With Cis ± Papillary Tumors

Immunitybio Announces NCCN Clinical Practice Guidelines in Oncology Have Been Updated to Include Anktiva Plus BCG for Patients with BCG-Unresponsive NMIBC with Papillary-Only Disease

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from over 60 Healthy and Cancer Donors

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

ImmunityBio, Inc. Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA®? Plus BCG Versus BCG Alone in BCG-Naive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio Receives Authorization from the European Commission for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

ImmunityBio, Inc. Reports Productive Regulatory Engagement with Saudi Food and Drug Authority At USA -Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

ImmunityBio, Inc. Launches Phase 2 Chemotherapy-FreeCAR-NK Cell Therapy Trial with Anktiva (ResQ215B) in Indolent Lymphomas

ImmunityBio, Inc. Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA Plus CAR-NK, Chemo-Free Therapy

Immunitybio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA in BCG-Unresponsive Papillary Bladder Cancer

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

Saudi Fda Grants Accelerated Approval to ImmunityBio , Inc.'s Anktiva for Non-Muscle Invasive Bladder Cancer Witharcinoma In-Situ

ImmunityBio, Inc. Announces Positive Results Demonstrating ANKTIVA as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmiBio, Inc. Announces Treatment with ANKTIVA®? (nogapendekin Alfa Inbakicept-pmln) Plus Bacillus Calmette-Guerin

ImmunityBio, Inc. Appoints Bruce Wendel to the Board, Effective December 12, 2025

Immunitybio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for Anktiva with Bcg for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. Announces its ANKTIVA Reverses Lymphopenia and Extends Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

ImmunityBio, Inc. Announces Initial Data Shows 100% Disease Control in 5 Out of 5 Patients with Recurrent Glioblastoma with Two Patients in Near Complete Response Treated with Immunotherapy's ANKTIVA®?, NK Cell Therapy Plus Optune Gio®? Device

ImmunityBio, Inc. Announces Phase 2 Study of ANKTIVA®? in Patients with Long COVID

Immunitybio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free

ImmunityBio, Inc. Announces Houston's Michael E. DeBakey Department of Veterans Affairs Medical Center Is Among the First VA Hospitals to Helpister ANKTIVA to Bladder Cancer Patients

ImmunityBio, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield™ Platform, in Patients with Solid Tumors

ImmunityBio, Inc. Receives Refusal to File Letter from the U.S. Food and Drug Administration for the Supplemental Biologics License Application

ImmunityBio, Inc., Annual General Meeting, Jun 18, 2025

ImmunityBio, Inc. Announces Positive Long-Term Results from Its Quilt-3.032 Study of Anktiva® (Nogapendekin Alfa Inbakicept-Guerin) Plus BCG

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA to Treat Lymphopenia

ImmunityBio, Inc. has filed a Follow-on Equity Offering in the amount of $75.000001 million.

Pomerantz LLP and Holzer & Holzer, LLC Announces Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

ImmunityBio, Inc. Announces First Dosing of Recombinant BCG in the U.S. and 60 Sites Are in the Process of Launching

ImmunityBio, Inc. Announces Certain Operational Results Following Approval of the Permanent J-Code (J9028) in January 2025

ImmunityBio, Inc. Receives FDA RMAT Designation for ANKTIVA and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-Of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

U.S. Food and Drug Administration Authorizes ImmunityBio, Inc. to Provide Recombinant BCG (rBCG) to Urologists to Address TICE BCG Shortage

Immunitybio, Inc. Announces Uk Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for Anktiva

John Owen Brennan Resigns as a Member of the Board of Directors and from All Committees of the Board of ImmunityBio, Inc

ImmunityBio, Inc. Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA®? for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Immunitybio, Inc. Announces Permanent J-Code (J9028) for Anktiva®? Is Now Effective

ImmunityBio, Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

ImmunityBio, Inc. has filed a Follow-on Equity Offering.

ImmunityBio, Inc. Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS

Third quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 3Q 2023)

ImmunityBio, Inc. Announces First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

New major risk - Financial position

Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.32 loss in 2Q 2023)

ImmunityBio, Inc.'s ANKTIVA® Now Covered by More Than a Dozen Insurance Plans Representing over 100 Million Lives Within Months of FDA Approval

ImmunityBio, Inc Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.27 loss in 1Q 2023)

ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Insufficient new directors

No longer forecast to breakeven

New minor risk - Profitability

Full year 2023 earnings released: US$1.15 loss per share (vs US$1.04 loss in FY 2022)

ImmunityBio Announces Data from A Phase 1 Pilot Study

ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Forecast to breakeven in 2026

Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes (PROs) of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG

New major risk - Financial position